web analytics
10.1 C
Munich
Friday, October 7, 2022

NuGene International Inc (OTCBB:NUGN) Takes Center Stage

NuGene International Inc (OTCBB:NUGN) may have started off slow but it has recently transformed into a volume leader and one of the top traded stocks on the entire bb’s.

On May 18 NUGN announced its Quarterly Report for the three months ended March 31, 2015. CEO Ali Kharazmi said “We achieved important milestones in the first quarter of 2015. During this quarter we:

— Reported $481,360 of sales
— Relocated to an 11,000 square foot office, research, manufacturing and assembly location in Orange County, California
— Invested approximately $83,000 in laboratory and office equipment and leasehold improvements to our new facility
— Generated all first quarter revenues from our NuGene product lines, effectively diversifying our revenue streams away from affiliated transactions
— Formed NuGene BioPharma for biopharmaceutical development
— Acquired SkinGuardian(R) as a platform to further develop our advanced skin and wound treatments
— Continued to attract industry luminaries to our Advisory Board
— Launched NuGene kathy ireland(R) branded products promotion on nationally syndicated television show (Extra)
— Initiated development of mass retail sales model for NuGene kathy ireland(R) brand
— Commenced the development of an ‘in-house’ sales team.”

NuGene International Inc (OTCBB:NUGN) specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.

According to NUGN the US Department of Health and Human Services calls regenerative medicine the “next evolution of medical treatments.” The regenerative medical market, which includes cosmeceuticals and pharmaceuticals, was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.

NuGene’s cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene’s exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has two patents pending covering 15 unique applications and inventions. NuGene’s goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

In March NGUN announced that its subsidiary corporation, NuGene BioPharma, Inc. has acquired all rights, title and interest in and to SkinGuardian®, an FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream.

NuGene BioPharma acquired all intellectual property held by SkinGuardian and its founder and owner, Chris O’Brien, relating to the SkinGuardian technology and applications. This includes the patent under which the technology is protected, the company trademark, all formulas and derivatives under the patent, clinical trial data, and any and all other rights, title and interest in and to the SkinGuardian product. Under the agreement, O’Brien will provide ongoing consultation to NuGene International, Inc.

CEO Ali Kharazmi said “We see this FDA-approved topical cream as the foundation for a variety of topical treatments we will be developing that incorporate the use of stem cells to enhance healing,” Kharazmi continued. “This is a prime example of the type of synergistic acquisitions we intend to make that will expand our range of opportunities while significantly reducing our time to market.”

On April 6 NGUN announced the filing on March 30, 2015 of its Annual Report on Form 10-K for the year ended December 31, 2014. According to NUGN CEO Ali Kharazmi. “Among our important milestones:

  • We began selling our proprietary regenerative skin and hair care products to a growing base of aestheticians, skin and hair care professionals and medical spas.
    We became a publicly traded company.
    We entered into a licensing agreement with kathy ireland Worldwide®.
    We grew sales from $155,197 in 2013 to $723,438 in 2014 – a significant increase.
    We fortified our balance sheet, with total assets at yearend of $1.86 million compared to total liabilities of $492,563.
    We added key members to our Advisory Board.
    We secured 11,000 square feet of new office and warehouse space in Irvine, California to support our planned expansion and growth.

Also of importance here (thanks to Hotstocked) is the 148,200 shares of Bling Marketing that were acquired on March 27, 2014 for just $37,050. After the forward splits these shares are now 11,144,640 free trading shares of NGUN.

Currently trading at a $80 million market valuation NUGN does have $1.3 million in the treasury and growing revenues reporting $723,438 in sales in 2014. Volume on NGUN has increased significantly in recent days and the stock has been moving up steadily with the look and feel of a significant promotion in the early stages. We will be updating on NGUN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NGUN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in NUGN either long or short and we have not been compensated for this article.

More articles

2 COMMENTS

  1. Terrible customer service received Nugn starter Kit from dermal store. Received damaged (shampoo leaked every where and box was very hot.). Called customer service left on hold they did not know what to do. Important to mention shipped by Amazon delivered by UPS. Dermal store in Vegas just takes money but does not care about customer

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.